Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study

Shah1,*, François Guilhot2, Jorge E. Cortes3, Charles A. Schiffer4, Philipp le Coutre5, Tim H. Brümmendorf6, Hagop M. Kantarjian3, Andreas Hochhaus7, Philippe Rousselot8, Hesham Mohamed9, Diane Healey10, Michael Cunningham10, and Giuseppe Saglio11
+ Author Affiliations

Key points

* Imatinib-resistant/-intolerant patients with chronic myeloid leukemia in chronic phase can experience long-term benefit with dasatinib.

* Early (3- and 6-month) molecular and cytogenetic responses were associated with improved progression-free survival and overall survival.

http://bloodjournal.hematologylibrary.org/content/early/2014/02/25/blood...